Hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery (CRS) holds promise as an adjunctive treatment strategy in malignancies affecting the peritoneal surface, effectively targeting remaining microscopic residual tumor. HIPEC increases concentrations of chemotherapy directly within the peritoneal cavity compared with the intravenous route and reduces the systemic side effects associated with prolonged adjuvant intraperitoneal exposure. Furthermore, hyperthermia increases tissue penetration and is synergistic with the therapeutic chemotherapy agents used. In ovarian cancer, evidence is building for its use in both primary and recurrent scenarios.”.
To read more about this study, click here.
Search Surgeon by State
HIPEC Ovarian Cancer Patients Share Their Stories
Dena Svoboda, 56, never expected a bad case of acid reflux would turn out to be cancer. “I thought it was a gallbladder issue, but it wasn’t,” said Dena, of Sagamore Hills, Ohio. “It ended up being a 25-pound tumor.”
Julie Khoury, was treated with HIPEC during surgery to treat Ovarian Cancer. She is a Patient of Dr. Shanel Bhagwandin of Jupiter Medical Center.
Isabel Navas now has countless holidays to look forward to, but just over a year ago she was told to get her affairs in order after an ominous diagnosis.
“Well, you’ve got a tumor” were his first words to me. I had just awakened in a hospital bed on the morning after emergency surgery. It was Tuesday, Oct. 31, 2017. Halloween.
Lori Moon, of Lincoln, was treated with HIPEC during surgery to treat Ovarian Cancer. She is a Patient of Dr. Thomas Minor of Rhode Island Hospital.
“While I knew something was wrong, I would never have guessed ovarian cancer,” Henri said. “It just seemed impossible that I could have it when I had no ovaries.” “
The first line in the treatment and diagnosis of ovarian cancer at Cancer Treatment Centers of America® (CTCA) is often surgery.